Cited by 293Down syndrome and intellectual disability researchAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Down syndrome and Alzheimer's disease: Common pathways, common goals

Open access

Hartley, Dean, Blumenthal, Thomas, Carrillo, Maria, DiPaolo, Gilbert, Esralew, Lucille, Gardiner, Katheleen, Granholm, Ann-Charlotte, Iqbal, Khalid, Krams, Michael, Lemere, Cynthia, Lott, Ira, Mobley, William, Ness, Seth, Nixon, Ralph, Potter, Huntington, Reeves, Roger, Sabbagh, Marwan, Silverman, Wayne, Tycko, Benjamin, Whitten, Michelle, Wisniewski, Thomas·2015·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2014.10.007PMC PMC4817997

Open this paper in CoChat — free account

Abstract

In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease‐modifying treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2014.10.007

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED AND REPLACED: Nerve growth factor metabolic dysfunction in Down’s syndrome brains
Iulita, M. F., Carmo, S. D., Ower, A. K., Fortress, A. M., Aguilar, L. F., Hanna, M., Wısnıewskı, T., Granholm, A., Buhusi, M. C., Busciglio, J. A., et al. (2014) · Brain · doi:10.1093/brain/awt372 · Cited by 94
Self-citation
Retracted
Inhibition and impulsivity: behavioral and neural basis of response control
Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Endocytic Pathway Abnormalities Precede Amyloid β Deposition in Sporadic Alzheimer’s Disease and Down Syndrome
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776
Self-citation
Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease
Rumble, B. A., Retallack, R. W., Hilbich, C., Simms, G., Multhaup, G., Martins, R. N., Hockey, A., Montgomery, P., Beyreuther, K. T., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 656
Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584
Self-citation
A Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561
Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration
Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543
Self-citation
Cognitive deficits and associated neurological complications in individuals with Down's syndrome
Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484
Self-citation

Show all 80 references

Sorted by citations

The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
Alzheimer's disease
López, J. A., González, H. M., & Léger, G. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 887
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Self-citation
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Weiner, M. W., Veitch, D. P., Aisen, P. S. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Morris, J. C., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 325
Aducanumab: Appropriate Use Recommendations
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.41 · Cited by 316
Dishing out mini-brains: Current progress and future prospects in brain organoid research
Kelava, I., & Lancaster, M. A. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.06.037 · Cited by 323
Down syndrome and the complexity of genome dosage imbalance
Antonarakis, S. E. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.154 · Cited by 314
Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 304
Self-citation
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
Self-citation
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination
Olmos-Serrano, J. L., Kang, H. J., Tyler, W. A., Silbereis, J. C., Cheng, F., Zhu, Y., Pletikos, M., Jankovic-Rapan, L., Cramer, N. P., Galdzicki, Z., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.042 · Cited by 239
“…phenotypes affecting many organ systems, including CNS abnormalities such as cognitive and motor impairments, microcephaly, and the early appearance of neuropathological characteristics of Alzheimer’s disease (AD; Hartley et al., 2015; Haydar and Reeves, 2012; Letourneau et al., 2014; Lott, 2012).”
Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity
Araya, P., Waugh, K. A., Sullivan, K. D., Núñez, N. G., Roselli, E., Smith, K. P., Granrath, R. E., Rachubinski, A. L., Enriquez Estrada, B., Butcher, E. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908129116 · Cited by 179
Early and Late CNS Inflammation in Alzheimer’s Disease: Two Extremes of a Continuum?
Cuello, A. C. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.005 · Cited by 170
Alzheimer Disease and Its Growing Epidemic
Hickman, R. A., Faustin, A., & Wısnıewskı, T. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.009 · Cited by 163
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 161
Outcome Measures for Clinical Trials in Down Syndrome
Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d'Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.247 · Cited by 153
Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome
Waugh, K. A., Araya, P., Pandey, A., Jordan, K. R., Smith, K. P., Granrath, R. E., Khanal, S., Butcher, E. T., Estrada, B. E., Rachubinski, A. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.038 · Cited by 150
Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview
Varesi, A., Carrara, A., Pires, V. G., Floris, V., Pierella, E., Savioli, G., Prasad, S., Esposito, C., Ricevuti, G., Chirumbolo, S., et al. (2022) · Cells · doi:10.3390/cells11081367 · Cited by 150
Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors
Powers, R. K., Culp‐Hill, R., Ludwig, M. P., Smith, K. P., Waugh, K. A., Minter, R., Tuttle, K. D., Lewis, H. C., Rachubinski, A. L., Granrath, R. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12739-9 · Cited by 141
Medical vulnerability of individuals with Down syndrome to severe COVID-19–data from the Trisomy 21 Research Society and the UK ISARIC4C survey
Hüls, A., Costa, A. C. S., Dierssen, M., Baksh, R. A., Bargagna, S., Baumer, N., Brandão, A. C., Carfì, A., Carmona‐Iragui, M., Chicoine, B. A., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100769 · Cited by 134
Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129
Self-citation
APOE-amyloid interaction: Therapeutic targets
Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131
The implications of exosomes in pregnancy: emerging as new diagnostic markers and therapeutics targets
Ghafourian, M., Mahdavi, R., Jonoush, Z. A., Sadeghi, M., Ghadiri, N., Farzaneh, M., & Salehi, A. M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00853-z · Cited by 133
mTOR hyperactivation in Down Syndrome underlies deficits in autophagy induction, autophagosome formation, and mitophagy
Bordi, M., Darji, S., Sato, Y., Mellén, M., Berg, M. J., Kumar, A., Jiang, Y., & Nixon, R. A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1752-5 · Cited by 124
Self-citation
The prevalence and incidence of early‐onset dementia among adults with autism spectrum disorder
Vivanti, G., Tao, S., Lyall, K., Robins, D. L., & Shea, L. (2021) · Autism Research · doi:10.1002/aur.2590 · Cited by 143
Contributions of DNA Damage to Alzheimer’s Disease
Lin, X., Kapoor, A., Gu, Y., Chow, M. J., Peng, J., Zhao, K., & Tang, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051666 · Cited by 117
The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies
Lautarescu, A., Holland, A. J., & Zaman, S. H. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9341-9 · Cited by 115
Cerebrovascular pathology in Down syndrome and Alzheimer disease
Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., & Lott, I. T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0499-4 · Cited by 105
Self-citation
Further understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Self-citation
Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions
Dierssen, M., Fructuoso, M., de Lagrán, M. M., Marzia Perluigi, A., & Barone, E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00670 · Cited by 106
Immunotherapy for Alzheimer's disease
Wısnıewskı, T., & Goñi, F. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.020 · Cited by 103
Alzheimer's Disease in the Down Syndrome: An Overview of Genetics and Molecular Aspects
Gomes, F. D. C., Mattos, M. F., Goloni‐Bertollo, E. M., & Pavarino, É. C. (2021) · Neurology India · doi:10.4103/0028-3886.310062 · Cited by 104
Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis
Zhang, Y., Che, M., Yuan, J., Yu, Y., Cao, C., Qin, X.-Y., & Cheng, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21060 · Cited by 98
Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer’s Disease Pathogenesis
Garbuz, D. G., Zatsepina, O. G., & Evgen’ev, M. B. (2021) · Molecular Biology · doi:10.1134/s002689332104004x · Cited by 95
Changes in cognitive function after a 12-week exercise intervention in adults with Down syndrome
Ptomey, L. T., Szabo‐Reed, A. N., Willis, E. A., Gorczyca, A. M., Greene, J. L., Danon, J. C., & Donnelly, J. E. (2018) · Disability and health journal · doi:10.1016/j.dhjo.2018.02.003 · Cited by 93
Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein
Gómez, W., Morales, R., Maracaja‐Coutinho, V., Parra, V., & Nassif, M. (2020) · Aging · doi:10.18632/aging.102677 · Cited by 94
Internal m7G methylation: A novel epitranscriptomic contributor in brain development and diseases
Xia, X., Wang, Y., & Zheng, J. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.003 · Cited by 87
Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders
Batarseh, Y. S., Duong, Q.-V., Mousa, Y. M., Rihani, S. B. A., Elfakhri, K. H., & Kaddoumi, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030338 · Cited by 82
Exosomal biomarkers in Down syndrome and Alzheimer's disease
Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.028 · Cited by 80
Self-citation
β2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function
Gao, Y., Hong, Y., Huang, L., Zheng, S., Zhang, H., Wang, S., Yao, Y., Zhao, Y., Zhu, L., Xu, Q., et al. (2023) · Cell · doi:10.1016/j.cell.2023.01.021 · Cited by 75
Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease
Strupp, B. J., Powers, B. E., Velázquez, R., Ash, J. A., Kelley, C. M., Alldred, M. J., Strawderman, M. S., Caudill, M. A., Mufson, E. J., & Ginsberg, S. D. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921100311 · Cited by 72
Editorial (Thematic Issue: The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective)
Salehi, A., Ashford, J. W., & Mufson, E. J. (2015) · Current Alzheimer Research · doi:10.2174/1567205012999151021102914 · Cited by 79
JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome
Tuttle, K. D., Waugh, K. A., Araya, P., Minter, R., Orlicky, D. J., Ludwig, M., Andrysik, Z., Burchill, M. A., Tamburini, B. A. J., Sempeck, C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108407 · Cited by 72
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study
Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E. W., Christian, B. T., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00139-3 · Cited by 70
Self-citation
Aging with Down Syndrome—Where Are We Now and Where Are We Going?
Alldred, M. J., Martini, A. C., Patterson, D., Hendrix, J. A., & Granholm, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204687 · Cited by 72
Self-citation
Nanomedicine-based immunotherapy for central nervous system disorders
Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 69
Trans-Acting Epigenetic Effects of Chromosomal Aneuploidies: Lessons From Down Syndrome and Mouse Models
Do, C., Xing, Z., Yu, Y. E., & Tycko, B. (2016) · Epigenomics · doi:10.2217/epi-2016-0138 · Cited by 66
Self-citation
Distribution of microglial phenotypes as a function of age and Alzheimer's disease neuropathology in the brains of people with Down syndrome
Martini, A. C., Helman, A. M., McCarty, K. L., Lott, I. T., Doran, E., Schmitt, F. A., & Head, E. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12113 · Cited by 66
Self-citation
Insights into the Potential Role of Mercury in Alzheimer’s Disease
Bjørklund, G., Tinkov, A. A., Dadar, M., Rahman, M. M., Chirumbolo, S., Skalny, A. V., Геннадиевна, С. М., Haley, B. E., Ajsuvakova, O. P., & Aaseth, J. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01274-3 · Cited by 64
Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance
Rhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63
Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
Chung, H., Green, P. H. R., Wang, T. C., & Kong, X. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s280953 · Cited by 59
Perinatal Choline Supplementation Reduces Amyloidosis and Increases Choline Acetyltransferase Expression in the Hippocampus of the APPswePS1dE9 Alzheimer's Disease Model Mice
Mellott, T. J., Huleatt, O. M., Shade, B. N., Pender, S. M., Liu, Y. B., Slack, B. E., & Blusztajn, J. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170450 · Cited by 54
A neuronal blood marker is associated with mortality in old age
Kaeser, S. A., Lehallier, B., Thinggaard, M., Häsler, L. M., Apel, A., Bergmann, C., Berdnik, D., Jeune, B., Christensen, K., Grönke, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00028-4 · Cited by 62
Neurogenetic disorders across the lifespan: from aberrant development to degeneration
Hickman, R. A., O’Shea, S. A., Mehler, M. F., & Chung, W. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00595-5 · Cited by 59
Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease
Potter, H., Granic, A., & Caneus, J. (2015) · Current Alzheimer Research · doi:10.2174/156720501301151207100616 · Cited by 54
Self-citation
Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental Disorders
Potter, H., Chial, H. J., Caneus, J., Elos, M. T., Elder, N., Borysov, S. I., & Granic, A. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01092 · Cited by 52
Self-citation
Mitochondria break free: Mitochondria-derived vesicles in aging and associated conditions
Ferrucci, L., Guerra, F., Bucci, C., Marzetti, E., & Picca, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102549 · Cited by 58
CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer’s disease
Mendióroz, M., Celarain, N., Altuna, M., de Gordoa, J. S., Zelaya, M. V., Roldán, M., Rubio, I., Larumbe, R., Erro, M. E., Méndez-López, I., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0183-0 · Cited by 51
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
Self-citation
Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine
Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
Enhancing teaching and learning in STEM Labs: The development of an android-based virtual reality platform
Laseinde, O. T., & Dada, D. (2023) · Materials Today Proceedings · doi:10.1016/j.matpr.2023.09.020 · Cited by 48
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome
Belichenko, P., Madani, R., Rey-Bellet, L., Pihlgren, M., Becker, A., Plassard, A., Vuillermot, S., Giriens, V., Nosheny, R., Kleschevnikov, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152471 · Cited by 35
Self-citation
Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer’s Disease
Helman, A. M., Siever, M., McCarty, K. L., Lott, I. T., Doran, E. W., Abner, E. L., Schmitt, F. A., & Head, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180589 · Cited by 49
Self-citation
Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies
Langerscheidt, F., Wied, T., Kabbani, M. A. A., van Eimeren, T., Wunderlich, G., & Zempel, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12314-3 · Cited by 52
Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
Kamer, A. R., Fortea, J., Videla, S., Mayoral, A., Janal, M. N., Carmona‐Iragui, M., Benejam, B., Craig, R. G., Saxena, D. B., Corby, P. M. A., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.01.001 · Cited by 49
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 46
Prevalence of dementia in people with intellectual disabilities: Cross‐sectional study
Takenoshita, S., Terada, S., Kuwano, R., Inoue, T., Cyoju, A., Suemitsu, S., & Yamada, N. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5258 · Cited by 47
Dissecting Alzheimer disease in Down syndrome using mouse models
Choong, X. Y., Tosh, J., Pulford, L. J., & Fisher, E. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 41
Longitudinal measures of cognition in the Ts65Dn mouse: Refining windows and defining modalities for therapeutic intervention in Down syndrome
Olmos-Serrano, J. L., Tyler, W. A., Cabral, H., & Haydar, T. F. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.005 · Cited by 41
Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
Nyberg, L. H., Lundquist, A., Adolfsson, A. N., Andersson, M., Zetterberg, H., Blennow, K., & Adolfsson, R. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12050 · Cited by 42
Neuropsychological and neurophysiological characterization of mild cognitive impairment and Alzheimer's disease in Down syndrome
García-Alba, J., Ramírez‐Toraño, F., Esteba‐Castillo, S., Bruña, R., Moldenhauer, F., Novell, R., Romero-Medina, V., Maestú, F., & Fernández, A. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.07.017 · Cited by 41
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
Dekker, A. D., Fortea, J., Blesa, R., & Deyn, P. P. D. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.02.006 · Cited by 42
The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease
Rujeedawa, T., Félez, E. C., Clare, I. C. H., Fortea, J., Strydom, A., Rebillat, A., Coppus, A. M. W., Levin, J., & Zaman, S. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194582 · Cited by 43
Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer’s disease and not in other tauopathies
Pires, G., McElligott, S., Drusinsky, S., Halliday, G. M., Potier, M., Wısnıewskı, T., & Drummond, E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0848-6 · Cited by 41
Mechanistic insights into the role of herpes simplex virus 1 in Alzheimer’s disease
Feng, S., Liu, Y., Zhou, Y., Shu, Z., Cheng, Z., Brenner, C., & Feng, P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1245904 · Cited by 36
Down syndrome and microRNAs (Review)
s, A. B. ⁄., Rodrigues, A., Gomes, B. C., & Rueff, J. (2017) · Biomedical Reports · doi:10.3892/br.2017.1019 · Cited by 36
Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules
Lanzillotta, C., & Domenico, F. D. (2021) · Biomolecules · doi:10.3390/biom11020266 · Cited by 36
Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer’s Disease
Alldred, M. J., Penikalapati, S. C., Lee, S. H., Heguy, A., Roussos, P., & Ginsberg, S. D. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02453-3 · Cited by 38
Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease
Tentolouris-Piperas, V., Ryan, N. S., Thomas, D. L., & Kinnunen, K. M. (2016) · Brain Research · doi:10.1016/j.brainres.2016.11.011 · Cited by 38
CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation
Alldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., & Ginsberg, S. D. (2018) · Hippocampus · doi:10.1002/hipo.22832 · Cited by 35
Developmental deficits and staging of dynamics of age associated Alzheimer’s disease neurodegeneration and neuronal loss in subjects with Down syndrome
Węgiel, J., Flory, M. J., Kuchna, I., Nowicki, K., Wegiel, J., Ma, S. Y., Zhong, N., Wierzba‐Bobrowicz, T., de Leon, M., Lai, F., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01300-9 · Cited by 35
Self-citation
Oxidative Phosphorylation Is Dysregulated Within the Basocortical Circuit in a 6-month old Mouse Model of Down Syndrome and Alzheimer’s Disease
Alldred, M. J., Lee, S. H., Stutzmann, G. E., & Ginsberg, S. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.707950 · Cited by 34
Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease
Calero, M., Gómez‐Ramos, A., Calero, O., Soriano, E., Ávila, J., & Medina, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00138 · Cited by 38
Informant-based assessment instruments for dementia in people with intellectual disability: A systematic review and standardised evaluation
Zeilinger, E. L., Novaković, I. Z., Komenda-Schned, S., Franken, F., Sobisch, M., Mayer, A., Neumann, L. C., Loosli, S. V., Hoare, S., & Pietschnig, J. (2021) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2021.104148 · Cited by 34
Nanomedicine-based immunotherapy for Alzheimer's disease
Hoque, M., Samanta, A., Alam, S. S. M., Zughaibi, T. A., Kamal, M. A., & Tabrez, S. S. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104973 · Cited by 31
Mouse-based genetic modeling and analysis of Down syndrome
Xing, Z., Li, Y., Pao, A., Bennett, A. S., Tycko, B., Mobley, W. C., & Yu, Y. E. (2016) · British Medical Bulletin · doi:10.1093/bmb/ldw040 · Cited by 32
Self-citation
Aging With Down Syndrome: The Dual Diagnosis: Alzheimer’s Disease and Down Syndrome
Cipriani, G., Danti, S., Carlesi, C., & Fiorino, M. D. (2018) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317518761093 · Cited by 32
Long‐term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease
Alldred, M. J., Chao, H. M., Lee, S. H., Beilin, J., Powers, B. E., Petkova, E., Strupp, B. J., & Ginsberg, S. D. (2019) · The FASEB Journal · doi:10.1096/fj.201802669rr · Cited by 29
Mitochondria Have Made a Long Evolutionary Path from Ancient Bacteria Immigrants within Eukaryotic Cells to Essential Cellular Hosts and Key Players in Human Health and Disease
Atlante, A., & Valenti, D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050283 · Cited by 31
Novel method for collecting hippocampal interstitial fluid extracellular vesicles (EV ISF ) reveals sex‐dependent changes in microglial EV proteome in response to Aβ pathology
Pait, M. C., Kaye, S. D., Su, Y., Kumar, A., Singh, S., Gironda, S. C., Vincent, S., Anwar, M., Carroll, C. M., Snipes, J. A., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12398 · Cited by 29
Cholinergic neurodegeneration in Alzheimer disease mouse models
Shekari, A., & Fahnestock, M. L. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00013-7 · Cited by 30
Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
Kazim, S. F., Blanchard, J., Bianchi, R., & Iqbal, K. (2017) · Scientific Reports · doi:10.1038/srep45561 · Cited by 28
Self-citation
The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice
Ahmed, M. M., Wang, A. C., Elos, M. T., Chial, H. J., Sillau, S., Solano, D. A., Coughlan, C. M., Aghili, L., Anton, P. E., Markham, N. E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105694 · Cited by 31
Self-citation
Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues
London, J., Rouch, C., Bui, L. C., Assayag, E., Souchet, B., Daubigney, F., Medjaoui, H., Luquet, S. H., Magnan, C., Delabar, J. M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0591-6 · Cited by 29
Plasma Neurofilament Light and Alzheimer’s Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)
Rafii, M. S., Donohue, M., Matthews, D. C., Muranevici, G., Ness, S. L., O’Bryant, S. E., & Rissman, R. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190322 · Cited by 26
Self-citation
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
Lemoine, L., Ledreux, A., Mufson, E. J., Perez, S. E., Šimić, G., Doran, E. W., Lott, I. T., Carroll, S. L., Bharani, K., Thomas, S., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00414-3 · Cited by 29
Self-citation
Preventing Alzheimer’s: Our Most Urgent Health Care Priority
Sherzai, D., & Sherzai, A. Z. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827619843465 · Cited by 27
Maternal Choline Supplementation as a Potential Therapy for Down Syndrome: Assessment of Effects Throughout the Lifespan
Powers, B. E., Velázquez, R., Strawderman, M. S., Ginsberg, S. D., Mufson, E. J., & Strupp, B. J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.723046 · Cited by 22

Authors: Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., Lott, I., Mobley, W., Ness, S., Nixon, R., Potter, H., Reeves, R., Sabbagh, M., Silverman, W., Tycko, B., Whitten, M., & Wisniewski, T.
Affiliations: Alzheimer's Association (US)
University of Colorado Boulder (US)
Medical and Scientific Relations Alzheimer's Association Chicago IL USA
Department of Pathology and Cell Biology Columbia University Medical Center and The Taub Institute for Research on Alzheimer's Disease and The Aging Brain New York NY USA
Trinitas Regional Medical Center (US)
University of Colorado Anschutz (US)
Medical University of South Carolina (US)
Department of Neurochemistry New York State Institute for Basic Research in Developmental Disabilities New York NY USA
Janssen Research & Development (United States) (US)
Brigham and Women's Hospital (US)
University of California, Irvine (US)
University of California San Diego (US)
NYU Langone Health (US)
Johns Hopkins University (US)
Banner Health (US)
Kennedy Krieger Institute (US)
Columbia University Irving Medical Center (US)
Global Down Syndrome Foundation (US)
Department of Neurology, Pathology, and Psychiatry New York University, Langone Medical Center New York NY USA
Corresponding author: Hartley, Dean
ORCID: Hartley, Dean
Granholm, Ann-Charlotte
Iqbal, Khalid
Lemere, Cynthia
Lott, Ira
Mobley, William
Ness, Seth
Nixon, Ralph
Potter, Huntington
Reeves, Roger
Sabbagh, Marwan
Silverman, Wayne
Tycko, Benjamin
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2014-12-12
Volume: 11
Issue: 6
Pages: 700-709
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2014.10.007
PMC: PMC4817997
OpenAlex: W1991023630
Cited by: 290
References: 80
Citations by year: 2026: 12 · 2025: 26 · 2024: 24 · 2023: 33 · 2022: 27 · 2021: 46 · 2020: 27 · 2019: 26 · 2018: 15 · 2017: 19 · 2016: 20 · 2015: 13 · 2014: 2
FWCI: 17.91
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institute on Aging (R01AG012122, R01AG037942)
National Institute of Neurological Disorders and Stroke (R01NS076291)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Down syndrome, Alzheimer's disease
MeSH terms: Alzheimer Disease, Animals, Clinical Trials as Topic, Congresses as Topic, Disease Models, Animal, Down Syndrome, Humans, Neuropsychological Tests, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Down syndrome and Alzheimer's disease: Common pathways, common goals

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks